RxDoctor Payments Data

Katie Plourd

Nurse Practitioner · Cullman, ALNPI 1013259506

Payments from drug & device makers

$6,496in general payments, 2019–2025

Across 434 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$929
  • Pfizer$763
  • Johnson & Johnson$582
  • Gilead$484
  • Ardelyx, Inc.$385
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$6,33998%
  • Education$1572%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,496 in reported general payments places this provider in the 90th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$58,053
Medicare patients
317
Services billed
1,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir14$344,622
Cimzia (2 Pack)Certolizumab Pegol12$129,184
LinzessLinaclotide120$98,472
XifaxanRifaximin28$83,875
CreonLipase/Protease/Amylase17$69,426
IbsrelaTenapanor Hcl20$48,631
VemlidyTenofovir Alafenamide28$43,155
Dexlansoprazole DrDexlansoprazole69$20,843
TrulancePlecanatide23$20,613
Budesonide DrBudesonide68$10,122
Colestipol Hcl161$9,558
Mesalamine22$7,205
MotegrityPrucalopride Succinate14$6,936
PentasaMesalamine12$6,449
ErythromycinErythromycin Base24$6,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa, Vemlidy$484$387,77742 claims
AbbVieLinzess, Creon$2,029$167,898137 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$929$104,48851 claims
Ardelyx, Inc.Ibsrela$385$48,63120 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$163$6,93614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Cullman

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →